A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. 2017

K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
P95 Pharmacovigilance and Epidemiology Services,Koning Leopold III Laan 1,Leuven 3001,Belgium.

Surveillance systems for varicella in Europe are highly heterogeneous or completely absent. We estimated the varicella incidence based on seroprevalence data, as these data are largely available and not biased by under-reporting or underascertainment. We conducted a systematic literature search for varicella serological data in Europe prior to introduction of universal varicella immunization. Age-specific serological data were pooled by country and serological profiles estimated using the catalytic model with piecewise constant force of infection. From the estimated profiles, we derived the annual incidence of varicella infection (/100·000) for six age groups (<5, 5-9, 10-14, 15-19, 20-39 and 40-65 years). In total, 43 studies from 16 countries were identified. By the age of 15 years, over 90% of the population has been infected by varicella in all countries except for Greece (86·6%) and Italy (85·3%). Substantial variability across countries exists in the age-specific annual incidence of varicella primary infection among the <5 years old (from 7052 to 16 122 per 100 000) and 5-9 years old (from 3292 to 11 798 per 100 000). The apparent validity and robustness of our estimates highlight the importance of serological data for the characterization of varicella epidemiology, even in the absence of sampling or assay standardization.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D002644 Chickenpox A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed) Varicella,Chicken Pox
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D014645 Herpesvirus 3, Human The type species of VARICELLOVIRUS causing CHICKENPOX (varicella) and HERPES ZOSTER (shingles) in humans. Chickenpox Virus,Herpes zoster Virus,Ocular Herpes zoster Virus,VZ Virus,Varicella-Zoster Virus,HHV-3,Herpesvirus 3 (alpha), Human,Herpesvirus Varicellae,Human Herpesvirus 3,Chickenpox Viruses,Herpes zoster Viruses,VZ Viruses,Varicella Zoster Virus,Varicella-Zoster Viruses,Varicellae, Herpesvirus
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D016036 Seroepidemiologic Studies EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases. Seroprevalence,Seroepidemiologic Study,Seroepidemiological Study,Studies, Seroepidemiologic,Study, Seroepidemiologic,Seroepidemiological Studies,Seroprevalences,Studies, Seroepidemiological,Study, Seroepidemiological
D049673 History, 20th Century Time period from 1901 through 2000 of the common era. 20th Century History,20th Cent. History (Medicine),20th Cent. History of Medicine,20th Cent. Medicine,Historical Events, 20th Century,History of Medicine, 20th Cent.,History, Twentieth Century,Medical History, 20th Cent.,Medicine, 20th Cent.,20th Cent. Histories (Medicine),20th Century Histories,Cent. Histories, 20th (Medicine),Cent. History, 20th (Medicine),Century Histories, 20th,Century Histories, Twentieth,Century History, 20th,Century History, Twentieth,Histories, 20th Cent. (Medicine),Histories, 20th Century,Histories, Twentieth Century,History, 20th Cent. (Medicine),Twentieth Century Histories,Twentieth Century History

Related Publications

K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
April 2016, Vaccine,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
May 2002, Journal of viral hepatitis,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
April 2024, The Lancet regional health. Europe,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
January 2016, Academic pediatrics,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
January 2013, PloS one,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
March 2012, Indian pediatrics,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
January 2003, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
August 2022, PLoS medicine,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
July 2021, BMC health services research,
K Bollaerts, and M Riera-Montes, and U Heininger, and N Hens, and A Souverain, and T Verstraeten, and S Hartwig
November 2023, Vaccines,
Copied contents to your clipboard!